Record Semiconductor Revenue and Strong FY Financials
Full-year 2025 revenue was $664 million (down 7% YoY), while semiconductor revenue reached a record $477 million, up 2% YoY and representing 72% of total revenue. Full-year non-GAAP gross margin was 41%, operating income was $84 million, net income was $80 million, and diluted EPS was $1.33.
Substantial Backlog Increase Supporting 2026 Growth
Order backlog ended 2025 at $555 million, up $145 million (35% growth) year-over-year, providing strong visibility and positioning revenue growth primarily in the second half of 2026.
Aggressive 2026 Guidance Reflecting Momentum
Management guided full-year 2026 revenue to $740–$800 million (midpoint $770M, ~16% growth vs. 2025). Gross margin guide is 41–43% with diluted EPS of $1.50–$1.85, indicating management expects meaningful recovery and margin expansion.
Product Wins and Customer Traction (LSA, IBD, Propel, Lumina)
Notable product milestones include LSA evaluation system shipped to a second Tier 1 DRAM customer, two IBD300 evaluations extended into 2026, orders for the new Propel 300mm GaN-on-silicon system, and Lumina+ arsenide phosphide orders — all driving expected revenue growth in H2 2026 and beyond.
Advanced Packaging Surge
Advanced packaging revenue doubled to $150 million in 2025 from $75 million in 2024 (100% increase), driven by wet processing and lithography tool demand related to AI and heterogeneous integration.
Strong Cash Position and Operational Cash Flow
Cash and short-term investments totaled $390 million at year-end (up $21M sequentially). Cash flow from operations for the year was $69 million, and CapEx for 2025 totaled $16 million.
Market Exposure Aligned with AI and HPC Trends
Management highlighted secular growth opportunities: annealing SAM projected to $1.3B by 2029, IBD/EUV and pellicle SAM to $500M by 2029, and advanced packaging SAM to $650M by 2029. Leadership positions (e.g., production LSA at 3 Tier 1 logic customers and IBD EUV leadership) support these opportunities.
Shareholder Approval of Axcelis Merger
Shareholders approved the all-stock merger with Axcelis on February 6, 2026. Management expects to complete the transaction in H2 2026 subject to final regulatory clearance (China remains an outstanding approval).